Results 81 to 90 of about 10,911,887 (292)

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source

Immune checkpoint expression patterns on T cell subsets in light-chain amyloidosis: VISTA, PD-1, and TIGIT as potential therapeutic targets

Blood Science
Amyloid light chain (AL) amyloidosis is a rare plasma cell dyscrasia with dismal prognosis. This study aims to investigate the T-cell immune checkpoint expression patterns in systemic AL amyloidosis and its relationship with clinicobiological traits.
Jinghua Wang, Yujie Zhao, Pengjun Liao, Shuxin Huang, Youxue Huang, Shaohua Chen, Yangqiu Li, Liye Zhong   +7 more
doaj   +1 more source

Localized Gastrointestinal Light Chain (AL) Amyloidosis Under Surveillance for Five Years: A Case Report. [PDF]

DEN Open
ABSTRACT Amyloidosis, characterized by the deposition of abnormal protein fibrils in organs, is classified as systemic or localized. Amyloid light chain (AL)‐type localized amyloidosis is uncommon, particularly when confined to the gastrointestinal tract.
Kojimahara S, Tominaga K, Yamamiya A, Kanazawa M, Tanaka T, Sugaya T, Katoh N, Irisawa A.   +7 more
europepmc   +2 more sources

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Light Chain Cardiac Amyloidosis With Skeletal Muscle Weakness

JACC: Case Reports
Background: Amyloid light chain (AL) amyloidosis can manifest with heterogeneous, multisystem features. Cardiac involvement is common and drives prognosis.
Elyn Montgomery, BN, PhD, Natasha Gorrie, MD, Georgia McCaughan, BMedSc, MBBS, MMed, James Nadel, BA (Adv), MBBS (Hon I), MMed, PhD, Karan Shahi, MSc, N.K. Bart, MD, PhD, Antonia S. Carroll, BSc (Adv), MBBS   +6 more
doaj   +1 more source

Erythropoietin in Familial Amyloidosis ATTR V30M

, 2013
Familial amyloidosis ATTR V30M is an hereditary disorder, the most frequent type of transthyretin related amyloidosis. The main manifestation of the disease is a sensory-motor and autonomic polyneuropathy.
Costa, P.P., Beirão, I.
core   +1 more source

Resting State fMRI Reveals Diminished Functional Connectivity in a Mouse Model of Amyloidosis [PDF]

, 2013
Introduction: Functional connectivity (FC) studies have gained immense popularity in the evaluation of several neurological disorders, such as Alzheimer’s disease (AD). AD is a complex disorder, characterised by several pathological features. The problem
Rafael Delgado Y Palacios, Christian Bigot, Van Der Linden, Anne-Marie, Bigot, Christian, Van der Linden, Annemie, Rafael Delgado y Palacios (498616), Verhoye, Marleen, Disha Shah, Annemie Van der Linden, Christian Bigot (498617), Dany V D'Souza, Shah, Disha, Disha Shah (498613), Annemie Van der Linden (2227165), Elisabeth Jonckers, D'Souza, Dany V., Greetje Vanhoutte, Jonckers, Elisabeth, Jelle Praet (498614), Delgado y Palacios, Rafael, Greetje Vanhoutte (498615), Marleen Verhoye, Praet, Jelle, Marleen Verhoye (95635), Vanhoutte, Greetje, Jelle Praet, Elisabeth Jonckers (353117), Dany V. D’Souza (498618)   +27 more
core   +2 more sources

Prognostic role of high‐sensitivity cardiac troponin T in patients with cardiac sarcoidosis: insights from ILLUMINATE‐CS

ESC Heart Failure, Volume 12, Issue 2, Page 869-878, April 2025.
Abstract Aims The prognostic role of high‐sensitivity cardiac troponin T (hs‐cTnT) as a biomarker in patients with cardiac sarcoidosis (CS) has yet to be fully determined, especially when compared with B‐type natriuretic peptide (BNP). Methods and Results In this post‐hoc analysis of the ILLUMINATE‐CS (ILLUstration of the Management and prognosIs of ...
Yuichi Baba, Toru Kubo, Takeru Nabeta, Yuya Matsue, Takeshi Kitai, Yoshihisa Naruse, Tatsunori Taniguchi, Hidekazu Tanaka, Takahiro Okumura, Kenji Yoshioka, Hiroaki Kitaoka   +10 more
wiley   +1 more source

Masālik al-abṣār fī mamālik al-amṣār / li-Ibn-Faḍlallāh al-ʿUmarī. Bi-taḥqīq Aḥmad Zakī Bāšā

, 1924
Ersch.-Jahr auch 1342 h. -In arab.
Ibn-Faḍlallāh al-ʿUmarī, Aḥmad Ibn-Yaḥyā
core   +1 more source

Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 1176-1182, April 2025.
Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an increasinglyrecognized cause of heart failure with preserved ejection fraction (HFpEF), which may be diagnosed non‐invasively using 99mTc 3,3‐diphosphono‐1,2‐propanodicarboxylic acid (DPD) scintigraphy‐based diagnostic criteria.
L. Healy, G. Giblin, A. Gray, N. Starr, L. Murphy, D. O'Sullivan, E. Kavanagh, C. Howley, C. Tracey, E. Morrin, A. McDaid, A. Clarke, J.O. O'Neill, E. Joyce, M. O'Connell, N. G. Mahon   +15 more
wiley   +1 more source